Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas

BACKGROUND: To assess progression-free survival (PFS) as the appropriate end-point for phase II trials for anaplastic gliomas (AGs) and to determine the impact of PFS on survival-based phase III trials. METHODS: Combined data from 16 phase II studies (N = 529 patients) were analyzed to determine pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Victor A, Ictech, Sandra, Hess, Kenneth R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1919386/
https://www.ncbi.nlm.nih.gov/pubmed/17587447
http://dx.doi.org/10.1186/1471-2407-7-106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1919386/
https://www.ncbi.nlm.nih.gov/pubmed/17587447
http://dx.doi.org/10.1186/1471-2407-7-106

Ejemplares similares